Mabwell is signing an agreement with a strategic business partner for licensing and commercialization of denosumab biosimilar products in Malaysia. What Are the Biosimilars? The biosimilars, Mailishu and Maiweijian, reference the Amgen products Prolia and Xgeva, respectively. These drugs most commonly treat osteoporosis, particularly in post-menopausal women, or bone loss that occurs in patients following cancer treatment. The partner in this collaboration was not identified by name in ...